GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis.
Bogacki, Erin C et al.
Paper
Details
#GPNMB #lysosomaldysfunction #LRRK2

Biomarkers of LRRK2 and lysosomal dysfunction in Progressive Supranuclear Palsy
Allinson, K. S. et al.
Paper
Details
#LRRK2 #lysosomaldysfunction #PSP

Tau-441 Recombinant Tau-441 from rPeptide. High quality, >90% purity, batch to batch consistency. In stock and ready to ship - order online today.

To examine the implications of CMA dysfunction, rPeptide’s Tau-441 was used to assess #Tau behavior under these impaired conditions.

t.ly/2bKKW

This provides insight into the molecular links between #lysosomaldysfunction and #proteinaccumulation in #Parkinsons and #Alzheimers diseases.

New key genes in Parkinson's disease identified using CRISPR technology A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also car...

A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also carry such variants do not. #neuroskyence #Parkinson #Lysosomaldysfunction